The startup develops non-opioid pain therapies that target acute and chronic pain in patients with bleeding concerns, utilizing a clinically differentiated approach to manage painful inflammatory conditions. Their products offer measurable therapeutic advantages over traditional opioid treatments, enhancing patient safety and efficacy.
Funding
$115.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many patients experience acute and chronic pain that is inadequately managed by current standards of care, often leading to reliance on opioid therapies or drugs with potentially unsafe profiles. Treatment options are limited for individuals with bleeding concerns or those for whom traditional NSAIDs are not advised.
Solution
Tremeau Pharmaceuticals is dedicated to developing non-opioid pain therapies, specifically COX-2 selective NSAIDs, for patient populations with unmet medical needs. Their lead product, TRM-201 (rofecoxib), is a potent non-opioid analgesic with a well-established efficacy profile in multiple indications. Tremeau's approach focuses on indications where a COX-2 selective NSAID may offer therapeutic advantages over opioids, particularly in painful inflammatory conditions. They are also developing TRM-362 (deuterated etoricoxib), an investigational non-opioid pain treatment containing deuterated etoricoxib, which has demonstrated superior efficacy and tolerability compared to opioids in select acute pain conditions.
Target Audience
The primary target audience includes patients with acute and chronic pain, particularly those with bleeding concerns or for whom traditional NSAIDs are not advised, as well as healthcare professionals seeking non-opioid pain management options.
Features
- TRM-201 (rofecoxib): A COX-2 selective NSAID with a well-established efficacy profile.
- TRM-362 (deuterated etoricoxib): A deuterated form of etoricoxib designed to potentially alter the molecule’s metabolic profile while maintaining its core pharmacodynamic characteristics.
- Focus on patient populations whose pain management needs are not well-satisfied by the current standard of care.
- Development of therapies for indications where traditional NSAIDs may not be advised or opioids are frequently prescribed.
- TRM-201 is protected by U.S. Patent No. 10,945,992 (expiring May 2040), which broadly covers the PK profile of 17.5mg solid dosage forms of rofecoxib, and U.S. Patent No. 10,987,337 (expiring December 2039), which broadly covers highly purified rofecoxib.
- TRM-362 is protected by U.S. Patent No. 11,161,833, which provides compound patent protection through 2041.